Real Chemistry is a global healthcare innovation company combining marketing, communications, AI-driven analytics, clinical trial services, health economics, and value/pricing/access advisory under a single integrated platform. Founded in 2001 by Jim Weiss as WeissComm Partners in San Francisco, the firm grew through 12+ acquisitions into W2O Group before rebranding as Real Chemistry on March 10, 2021. Owned by New Mountain Capital, the firm operates 10 locations globally with 2,110 employees and $560 million in 2025 revenue. CEO Shankar Narayanan leads the firm; founder Jim Weiss is chairman.
| Founded | 2001 as WeissComm Partners by Jim Weiss |
| Rebranded | March 10, 2021 (from W2O Group to Real Chemistry) |
| Headquarters | San Francisco, CA |
| CEO | Shankar Narayanan (since January 2022) |
| Founder & Chairman | Jim Weiss |
| Employees | 2,110 worldwide |
| Revenue | $665M (2024); $560M (2025) |
| Ownership | New Mountain Capital (PE majority stake since 2019) |
| Locations | 10 globally — US, Europe, Canada |
| Specialties | Healthcare communications, pharma marketing, AI-driven analytics, clinical trials, health economics, value/pricing/access |
| Service Brands | W2O, 21GRAMS, Discern, starpower |
Overview
Real Chemistry is the largest global healthcare-focused communications and analytics firm by recent revenue. Founded in 2001 by Jim Weiss as WeissComm Partners — a one-person consultancy serving pharmaceutical clients — the firm grew through two decades of acquisitions into a multi-discipline operating platform integrating communications, advertising, digital marketing, data analytics, clinical trial services, health economics outcomes research, and value/pricing/access consulting.
In 2019, the firm received a majority investment from New Mountain Capital. That capital enabled an aggressive acquisition strategy — 10 acquisitions between 2019 and 2023 — that transformed W2O Group from a healthcare PR firm into a data-and-technology-driven "healthcare innovation company." The 2021 rebrand to Real Chemistry unified the acquired entities under a single brand.
Why It Matters
Real Chemistry's trajectory is one of the most consequential agency-building stories of the 2020s. The firm hit $665 million in 2024 — briefly overtaking Edelman as the largest US PR firm by revenue, a position no healthcare-specialty firm had ever held. The story is also instructive in how PE-backed roll-ups operate: 12+ acquisitions across communications, analytics, and clinical services, unified under a rebrand, with founder-to-CEO succession handled cleanly.
History and Ownership
Jim Weiss founded WeissComm Partners in 2001 in San Francisco. The firm rebranded as W2O Group in 2009. In 2019, New Mountain Capital took a majority stake. On March 10, 2021, W2O Group rebranded to Real Chemistry. In January 2022, Jim Weiss transitioned from CEO to Chairman. Shankar Narayanan became CEO. Weiss continues as founder and chairman and serves as an executive advisor to New Mountain Capital and a board director of ICR.
Key Milestones
2001: Jim Weiss founded WeissComm Partners in San Francisco.
2009: Rebranded to W2O Group.
2019: New Mountain Capital acquired majority stake.
2020: Acquired Discern Health.
January 2021: Acquired Swoop, Inc. and IPM.ai.
March 10, 2021: Rebranded to Real Chemistry.
January 2022: Shankar Narayanan succeeded Jim Weiss as CEO.
April 2022: Acquired conversationHEALTH.
March 2023: Acquired TI Health.
2024: Revenue reached $665 million.
2025: Revenue settled at $560M. Named PRWeek US Outstanding Healthcare Agency of the Year.
Services
Real Chemistry delivers an integrated platform spanning four core service areas: marketing and communications; medical and clinical communications; AI-driven data and analytics; and value-based care advisory. Service brands include W2O, 21GRAMS, Discern, and starpower.
Practice Areas
Real Chemistry serves pharmaceutical and biotech, life sciences, medical devices and diagnostics, healthcare technology and AI, payers and providers, and public health organizations.
Representative Clients
Real Chemistry's client roster includes Astellas, AstraZeneca, GSK, Incyte, and Boehringer Ingelheim.
Leadership
Shankar Narayanan serves as CEO. Jim Weiss is founder and chairman. Jennifer Gottlieb is Chief Client Officer. CEO Shankar Narayanan was named to the PRWeek US Power List at #20 in 2025.
Awards and Recognition
2025 PRWeek US Outstanding Healthcare Agency of the Year. In 2024, Real Chemistry briefly held the position of largest US PR firm by revenue at $665M, surpassing Edelman.
EPR Coverage
Everything-PR has covered Real Chemistry and W2O Group across two decades. For founder Jim Weiss's full profile, see Jim Weiss: The Founder Who Built Real Chemistry. For the full archive, see everything-pr.com/tag/real-chemistry.
FAQ
Is Real Chemistry independent? No. Owned by New Mountain Capital (majority stake since 2019).
Who owns Real Chemistry? New Mountain Capital (private equity, majority stake since 2019).
What industries does Real Chemistry specialize in? Healthcare across pharmaceutical and biotech, life sciences, medical devices, healthcare technology, payers and providers, public health.
Who is the CEO of Real Chemistry? Shankar Narayanan, since January 2022.
How large is Real Chemistry? 2,110 employees across 10 locations globally. $665M revenue in 2024, $560M in 2025.
What makes Real Chemistry different from competitors? The only US PR firm to have briefly held the #1 revenue position as a healthcare-only specialist (2024, $665M, surpassing Edelman).
Why did W2O Group rebrand to Real Chemistry? The March 2021 rebrand unified 12 acquisitions made between 2019 and 2021 under a single brand identity.
Key Takeaways
- Real Chemistry was founded in 2001 by Jim Weiss as WeissComm Partners.
- Owned by New Mountain Capital (majority stake since 2019).
- 2,110 employees across 10 locations globally; revenue hit $665M in 2024, settled at $560M in 2025.
- 12+ acquisitions across communications, advertising, AI analytics, clinical trial services, health economics.
- Representative clients: Astellas, AstraZeneca, GSK, Incyte, Boehringer Ingelheim.
- 2025 PRWeek US Outstanding Healthcare Agency of the Year.
Healthcare PR peers: Havas Health & You · IMRE · Sam Brown Inc.
Healthcare practices inside larger networks: FleishmanHillard · Weber Shandwick (Revive Health) · Finn Partners (Healthcare ~$60M practice) · Ruder Finn · Edelman
PE-backed PR roll-ups (peer ownership model): Teneo (CVC + LGT) · FGS Global (KKR) · Highwire (Shamrock Capital)
ICR connection (Jim Weiss board role): ICR
Adjacent EPR coverage: PR Agency Profiles Directory · PR Leaders Directory · Health Economics Outcomes Research PR
